Equifax enters its July 15 earnings report with a clean 10% weekly gain behind it, a shrinking short base, and a Street consensus that remains broadly constructive — yet options traders have quietly shifted toward caution as the print approaches.
The lending market tells a decidedly unexciting story, which is itself noteworthy. Borrow availability on EFX has exploded to nearly 2,400% — meaning there are roughly 24 shares available to lend for every one currently borrowed. That's well above the 52-week floor of 620%, and it's continued to rise through the week. Cost to borrow has dropped 31% over seven days to just 0.33%, its lowest level in over a month. Short interest, at 4.6% of free float, has drifted down roughly 0.5% over the week and is near its low for the past 30 days. The overall picture here is one of bears backing away: the borrow market is loose, shorts are covering, and there's no sign of a squeeze dynamic building. The short score of 38.9 — ranking in the 38th percentile universe-wide — reinforces that read.
Options positioning tells a slightly different story, one worth tracking. The put/call ratio has edged above its 20-day average, running at 0.80 against a mean of 0.71 — about one standard deviation above normal. That's not extreme by any measure, particularly relative to the 52-week high of 1.52, but the direction of travel is clear: put demand has climbed steadily through June and into early July as the earnings date draws closer. Options traders are hedging into the print, even as the stock rallied hard this week.
The Street remains broadly bullish, and recent analyst activity has reinforced rather than challenged that view. UBS reiterated its Buy and held its $220 target on July 8. Needham reiterated its Buy at a more aggressive $265 this week. The lone dissent in recent weeks came from Mizuho, which trimmed its target from $222 to $210 while keeping an Outperform rating — and Wells Fargo made a similar trim from $230 to $220 in June. The pattern is one of selective target compression rather than conviction loss. The consensus mean target sits at $220.81, implying roughly 27% upside from the current $174.58. At a trailing P/E of 16.4 and EV/EBITDA of 10.4 — both of which have drifted lower over the past month — the valuation has become somewhat less stretched heading into results. The bull case rests on EBITDA margin expansion of 100 basis points and a recovery in mortgage-related revenue through FICO price increases. Bears point to declining origination volumes and the drag from stricter lending standards, which they argue could trim earnings by around 10%.
The most interesting institutional data point concerns Soroban Capital Partners, which reported adding over 3.1 million shares in Q1 — making it a top-ten holder with 3.5% of outstanding shares. That's a substantial new position from an active manager and one of the larger conviction moves visible in the ownership table. BlackRock also added modestly through Q2. On the insider side, the bulk of recent activity has been selling — CEO Mark Begor disposed of around $6.5 million in stock in late April, and the CFO sold $618K in early May. The net 90-day position is slightly positive in share terms, largely reflecting an EVP purchase in February, but the directional signal from C-suite activity is one of lightening rather than accumulation.
Earnings history adds texture to the setup. The Q1 print in late April moved the stock down nearly 10% on the day and a further 13% over the subsequent five sessions — a significant negative reaction. The May result was calmer, recovering 1.5% on the day though fading 9% over the following week. With the July 15 print now a week out, the interplay between the constructive analyst tone, the rising put hedge demand, and whether mortgage volumes show any stabilisation is the dominant question for EFX into results.
See the live data behind this article on ORTEX.
Open EFX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
